Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis : a multicentre, open-label, partially randomised, phase 2b trial

Loading...
Thumbnail Image

Authors

Tweed, Connor D.
Dawson, Rodney
Burger, Divan Aristo
Conradie, Almari
Crook, Angela M.
Mendel, Carl M.
Conradie, Francesca
Diacon, Andreas H.
Ntinginya, Nyanda E.
Everitt, Daniel E.

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier

Abstract

Please read abstract in the article.

Description

Keywords

Tuberculosis (TB), Bactericidal activity, Safety profile, Pyrazinamide, Bedaquiline (BDQ), Pretomanid (PA‐824), Moxifloxacin, Pulmonary tuberculosis

Sustainable Development Goals

Citation

Tweed, C.D., Dawson, R., Burger, D.A. et al. 2019, 'Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial', Lancet Respiratory Medicine, vol. 7, no. 12, pp. 1048-1058.